AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential treatment for vasomotor symptoms associated with menopause. The Phase 2 portion is a randomized, double-blind, placebo-controlled study designed to evaluate efficacy in 80 postmenopausal women. AbCellera anticipates top-line clinical results for both phases in Q3 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
- AbCellera Secures Global Settlement and Patent License Deal
- AbCellera to receive $36M upfront in patent litigation settlement with Bruker
- Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
- AbCellera Appoints Dr. Stephen Quake to Board